| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Crizotinib | GDSC1000 | pan-cancer | AAC | -0.012 | 0.8 |
| mRNA | BMS-509744 | GDSC1000 | pan-cancer | AAC | 0.012 | 0.8 |
| mRNA | Platin | CTRPv2 | pan-cancer | AAC | 0.0085 | 0.8 |
| mRNA | MS-275 | GDSC1000 | pan-cancer | AAC | 0.012 | 0.8 |
| mRNA | Axitinib | GDSC1000 | pan-cancer | AAC | -0.0079 | 0.8 |
| mRNA | BRD-A02303741 | CTRPv2 | pan-cancer | AAC | -0.0084 | 0.8 |
| mRNA | MLN4924 | GDSC1000 | pan-cancer | AAC | 0.0086 | 0.8 |
| mRNA | ABT-737 | CTRPv2 | pan-cancer | AAC | -0.0079 | 0.8 |
| mRNA | UNC1215 | GDSC1000 | pan-cancer | AAC | -0.0075 | 0.8 |
| mRNA | navitoclax:sorafenib (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0075 | 0.8 |